fpft-2216 (Fujimoto Pharmaceutical Corporation)
90
Structured Review
Fujimoto Pharmaceutical Corporation
fpft-2216
Fpft 2216, supplied by Fujimoto Pharmaceutical Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fpft-2216/fpft+2216/pmc10846380-62-0-6
Average 90 stars, based on 1 article reviews
Fpft 2216, supplied by Fujimoto Pharmaceutical Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fpft-2216/fpft+2216/pmc10846380-62-0-6
Average 90 stars, based on 1 article reviews
fpft-2216 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Synthesized:Article Title: Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs Article Snippet: Article Title: FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling Article Snippet: Activity Assay:Article Title: Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs Article Snippet: Article Title: FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling Article Snippet: Activation Assay:Article Title: Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs Article Snippet: Article Title: FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling Article Snippet: Cell Culture:Article Title: Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs Article Snippet: Article Title: FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling Article Snippet: Suspension:Article Title: Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs Article Snippet: Article Title: FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling Article Snippet: Membrane:Article Title: Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs Article Snippet: Article Title: FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling Article Snippet: Concentration Assay:Article Title: Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs Article Snippet: Article Title: FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling Article Snippet: Injection:Article Title: Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs Article Snippet: Article Title: FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling Article Snippet: |